secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001823239-25-000105
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce
--------------------------------------------------------------------------------

- Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
- Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.
- Withdrew 2025 revenue guidance pending new leadership's business review.
- CEO Bernd Brust recently appointed; EVP CCO Rebecca Buzzeo and EVP CAO Pete Leddy departing.
- Base business revenue (ex high-volume CleanCap) grew 5% YoY; positive free cash flow expected by H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/0001823239-25-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323925000105/mrvi-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001823239-25-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer